DLG5 Variants Do Not Influence Susceptibility to Inflammatory Bowel Disease in the Scottish Population

Overview

Journal Gut

Specialty Gastroenterology

Date 2005 Apr 22

PMID 15843420

Citations 16

Authors

C L Noble

E R Nimmo

H Drummond

L Smith

I D R Arnott

J Satsangi

Affiliations

Soon will be listed here.

Abstract

Introduction: Recent data have suggested that specific haplotypic variants of the DLG5 gene on chromosome 10q23 may be associated with susceptibility to inflammatory bowel disease (IBD) in Germany. Haplotype D, notably characterised by the presence of a G-->A substitution at nucleotide 113, was associated with susceptibility to Crohn's disease (CD) whereas an extended haplotype A conferred protection.

Aims: Association of DLG5 haplotypic variants with disease susceptibility, genotype-phenotype relationships, and epistasis with CARD15 was investigated in the Scottish population.

Patients And Methods: A total of 374 CD, 305 ulcerative colitis (UC), and 294 healthy controls (HC) were studied. Genotyping for the variants rs1248696 (113A, representing haplotype D) and the single nucleotide polymorphism tag rs2289311 (representing haplotype A) were typed using the Taqman system.

Results: On analysis of the DLG5 variant 113A, there were no associations with IBD when allelic frequency (11.4% IBD v 13.2% HC; p = 0.30) and carrier frequency (19.2% IBD v 24.6% HC; p = 0.069) were analysed. No associations were observed between 113A variant allelic frequency (p = 0.37), carrier frequency (p = 0.057), and CD. In fact, 113A heterozygosity rates were lower in CD (16%) and IBD (16.9%) than in HC (23%) (p = 0.029 and p = 0.033, respectively). No associations between DLG5 and UC were observed. Haplotype A was not protective and there was no evidence of epistasis between DLG5 and CARD15.

Conclusions: The present data contrast strongly with previous data from Germany. DLG5 113A is not associated with disease susceptibility and haplotype A does not confer resistance. Further work is required to evaluate the significance of DLG5 in other populations from geographically diverse regions.

Citing Articles

Facial Presentation of Crohn's Disease: Report of a Case.

Talebzadeh A, Talebzadeh N Cureus. 2023; 15(3):e36024.

PMID: 37051004 PMC: 10085536. DOI: 10.7759/cureus.36024.

Systematic meta-analyses and field synopsis of genetic and epigenetic studies in paediatric inflammatory bowel disease.

Li X, Song P, Timofeeva M, Meng X, Rudan I, Little J Sci Rep. 2016; 6:34076.

PMID: 27670835 PMC: 5037432. DOI: 10.1038/srep34076.

Meta-analysis of associations between DLG5 R30Q and P1371Q polymorphisms and susceptibility to inflammatory bowel disease.

Li Y, Chen P, Sun J, Huang J, Tie H, Li L Sci Rep. 2016; 6:33550.

PMID: 27633114 PMC: 5025715. DOI: 10.1038/srep33550.

Interaction of Crohn's disease susceptibility genes in an Australian paediatric cohort.

Wagner J, Sim W, Ellis J, Ong E, Catto-Smith A, Cameron D PLoS One. 2010; 5(11):e15376.

PMID: 21079743 PMC: 2975706. DOI: 10.1371/journal.pone.0015376.

The Crohn's disease susceptibility gene DLG5 as a member of the CARD interaction network.

Friedrichs F, Henckaerts L, Vermeire S, Kucharzik T, Seehafer T, Moller-Krull M J Mol Med (Berl). 2008; 86(4):423-32.

PMID: 18335190 DOI: 10.1007/s00109-008-0307-5.

References

Lesage S, Zouali H, Cezard J, Colombel J, Belaiche J, Almer S . CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002; 70(4):845-57. PMC: 379113. DOI: 10.1086/339432. View

Girardin S, Boneca I, Viala J, Chamaillard M, Labigne A, Thomas G . Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003; 278(11):8869-72. DOI: 10.1074/jbc.C200651200. View

Kobayashi K, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G . Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005; 307(5710):731-4. DOI: 10.1126/science.1104911. View

Bairead E, Harmon D, Curtis A, Kelly Y, OLeary C, Gardner M . Association of NOD2 with Crohn's disease in a homogenous Irish population. Eur J Hum Genet. 2003; 11(3):237-44. DOI: 10.1038/sj.ejhg.5200954. View

Shah G, Brugada R, Gonzalez O, Czernuszewicz G, Gibbs R, Bachinski L . The cloning, genomic organization and tissue expression profile of the human DLG5 gene. BMC Genomics. 2002; 3:6. PMC: 77411. DOI: 10.1186/1471-2164-3-6. View

Moore J . A global view of epistasis. Nat Genet. 2004; 37(1):13-4. DOI: 10.1038/ng0105-13. View

Torok H, Glas J, Tonenchi L, Mussack T, Folwaczny C . Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol. 2004; 112(1):85-91. DOI: 10.1016/j.clim.2004.03.002. View

Askling J, Grahnquist L, Ekbom A, Finkel Y . Incidence of paediatric Crohn's disease in Stockholm, Sweden. Lancet. 1999; 354(9185):1179. DOI: 10.1016/S0140-6736(99)02625-2. View

Lennard-Jones J . Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989; 170:2-6; discussion 16-9. DOI: 10.3109/00365528909091339. View

10.

Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J . Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem. 2003; 278(8):5509-12. DOI: 10.1074/jbc.C200673200. View

11.

Watanabe T, Kitani A, Murray P, Strober W . NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol. 2004; 5(8):800-8. DOI: 10.1038/ni1092. View

12.

Satsangi J, Chapman R, Haldar N, Donaldson P, Mitchell S, Simmons J . A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology. 2001; 121(1):124-30. DOI: 10.1053/gast.2001.25527. View

13.

Maeda S, Hsu L, Liu H, Bankston L, Iimura M, Kagnoff M . Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science. 2005; 307(5710):734-8. DOI: 10.1126/science.1103685. View

14.

Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y . Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology. 2002; 123(1):86-91. DOI: 10.1053/gast.2002.34155. View

15.

Bonen D, Cho J . The genetics of inflammatory bowel disease. Gastroenterology. 2003; 124(2):521-36. DOI: 10.1053/gast.2003.50045. View

16.

Sugimura M, Kinouchi Y, Takahashi S, Aihara H, Takagi S, Negoro K . CARD15/NOD2 mutational analysis in Japanese patients with Crohn's disease. Clin Genet. 2003; 63(2):160-2. DOI: 10.1046/j.0009-9163.2002.00174.x. View

17.

Barton G, Medzhitov R . Toll-like receptor signaling pathways. Science. 2003; 300(5625):1524-5. DOI: 10.1126/science.1085536. View

18.

Orchard T, Thiyagaraja S, Welsh K, Wordsworth B, Gaston J, Jewell D . Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 2000; 118(2):274-8. DOI: 10.1016/s0016-5085(00)70209-5. View

19.

Armitage E, Aldhous M, Anderson N, Drummond H, Riemersma R, Ghosh S . Incidence of juvenile-onset Crohn's disease in Scotland: association with northern latitude and affluence. Gastroenterology. 2004; 127(4):1051-7. DOI: 10.1053/j.gastro.2004.06.024. View

20.

Satsangi J, Morecroft J, Shah N, Nimmo E . Genetics of inflammatory bowel disease: scientific and clinical implications. Best Pract Res Clin Gastroenterol. 2003; 17(1):3-18. DOI: 10.1053/bega.2002.0349. View